Related Experiment Video
Updated: Apr 18, 2026

Ovarian Cancer Patient-Derived Organoid Models for Pre-Clinical Drug Testing
Published on: September 15, 2023
Mathematical models for absorption and efficacy of ovarian cancer treatments
Abstract:
The creation of personal and individualized anti-cancer treatments has been a major goal in the progression of cancer discovery as evident by the continuous research efforts in genetics and population based PK/PD studies. In this paper we use our clinical decision support tool, called ChemoDSS, to evaluate the effectiveness of three treatments recommended by the NCCN guidelines for ovarian cancer using pre-clinical data from the literature. In particular, we analyze the treatments of PC (i.e., Paclitaxel and Cispaltin), DC (i.e., Docetaxel and Carboplatin), and PBC (i.e., Paclitaxel, Bevacizumab, and Carboplatin). Our in silico analysis of the ovarian cancer treatments shows that PC was the most effective regimen for treating ovarian cancer compared to DC and PBC, which is consistent with literature findings. We demonstrate that we can successfully evaluate the effectiveness of the selected ovarian cancer treatment regimens using ChemoDSS.
Insights
This study evaluated ovarian cancer treatments using the ChemoDSS tool. Paclitaxel and Cisplatin (PC) showed the most effectiveness compared to Docetaxel and Carboplatin (DC) and Paclitaxel, Bevacizumab, and Carboplatin (PBC) regimens.
Area of Science:
- Oncology
- Pharmacology
- Bioinformatics
Background:
- Personalized anti-cancer treatments are a key goal in cancer research.
- Genetics and population-based pharmacokinetic/pharmacodynamic (PK/PD) studies drive advancements.
- Ovarian cancer treatment effectiveness requires ongoing evaluation.
Purpose of the Study:
- To evaluate the effectiveness of NCCN-recommended ovarian cancer treatments using a clinical decision support tool.
- To compare three specific regimens: Paclitaxel and Cisplatin (PC), Docetaxel and Carboplatin (DC), and Paclitaxel, Bevacizumab, and Carboplatin (PBC).
- To validate the ChemoDSS tool's capability in assessing anti-cancer treatment efficacy.
Main Methods:
- Utilized the ChemoDSS clinical decision support tool for in silico analysis.
- Analyzed pre-clinical data from scientific literature.
- Evaluated three National Comprehensive Cancer Network (NCCN) guideline-recommended treatment regimens for ovarian cancer.
Main Results:
- In silico analysis indicated that the Paclitaxel and Cisplatin (PC) regimen was the most effective among the evaluated treatments.
- The effectiveness of PC was found to be superior compared to the Docetaxel and Carboplatin (DC) and Paclitaxel, Bevacizumab, and Carboplatin (PBC) regimens.
- Results align with existing findings reported in the scientific literature.
Conclusions:
- The ChemoDSS tool can successfully evaluate the effectiveness of selected ovarian cancer treatment regimens.
- The study confirms the efficacy of the PC regimen for ovarian cancer treatment based on in silico analysis.
- This approach supports the development of individualized anti-cancer strategies.
Related Concept Videos
Cancer Survival Analysis
Pharmacokinetic Models: Overview
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
One-Compartment Open Model for Extravascular Administration: First-Order Absorption Model
Fundamental Mathematical Principles in Pharmacokinetics: Calculus and Graphs
On the other hand, integral calculus focuses on...

